{"nctId":"NCT00853749","briefTitle":"Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine","startDateStruct":{"date":"2009-05-05","type":"ACTUAL"},"conditions":["Invasive Pneumococcal Disease"],"count":89,"armGroups":[{"label":"Single","type":"OTHER","interventionNames":["Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)","Procedure: Blood draw"]}],"interventions":[{"name":"13-valent pneumococcal conjugate vaccine (13vPnC)","otherNames":[]},{"name":"Blood draw","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Fully vaccinated children who participated in a previous Wyeth study (Study D139-P506) and received a booster dose of either 23-valent pneumococcal polysaccharide vaccine (PPV23) or pneumococcal conjugate vaccine (PnCV) per the original protocol for that study.\n* Subjects must be in good health as determined by medical history, physical examination and clinical judgment.\n\nExclusion Criteria:\n\n* Known allergy to any component of the 7-valent pneumococcal conjugate vaccine (7vPnC) or 13-valent pneumococcal conjugate vaccine (13vPnC).\n* History of documented invasive pneumococcal disease (defined as a positive culture of S. pneumoniae from a normally sterile body site).\n* Any known or suspected disease or dysfunction of the immune system, including: HIV infection, Malignancy, Receipt of immunosuppressive therapy, Sickle cell hemoglobinopathy.\n* Receipt of immune-globulin within the past 3 months.\n* Receipt of either PSV or 7vPnCV since the completion of Study D139-P506.","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"7 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (mcg/mL) Measured 1 Month After Vaccination","description":"Percentage of participants achieving predefined antibody threshold ≥ 0.35 mcg/mL along with the corresponding 95 percent (%) Confidence Interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination","description":"Percentage of participants achieving OPA along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"97.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Response Measured 1 Month After Vaccination (Avidity Assay)","description":"Avidity assay had measurable range of 0.117 to 7.5. Results expressed as avidity index (AI). Geometric mean avidity presented for 3 common pneumococcal serotypes (serotype 6B, 19F, and 23F) and 2 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1 and 5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":null},{"groupId":"OG001","value":"4.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":null},{"groupId":"OG001","value":"5.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.43","spread":null},{"groupId":"OG001","value":"5.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":null},{"groupId":"OG001","value":"2.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"6.43","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Response Measured 1 Month After Vaccination (OPA)","description":"Antibody response as measured by OPA, 1 month after vaccination. Geometric mean titers (GMTs) calculated using all participants with available data for the specified blood draw. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2374","spread":null},{"groupId":"OG001","value":"3765","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11156","spread":null},{"groupId":"OG001","value":"11477","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1651","spread":null},{"groupId":"OG001","value":"1713","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3041","spread":null},{"groupId":"OG001","value":"3048","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3230","spread":null},{"groupId":"OG001","value":"5684","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1266","spread":null},{"groupId":"OG001","value":"1198","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1678","spread":null},{"groupId":"OG001","value":"2714","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"1087","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"719","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7060","spread":null},{"groupId":"OG001","value":"5034","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5835","spread":null},{"groupId":"OG001","value":"7887","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1256","spread":null},{"groupId":"OG001","value":"1556","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal IgG Antibody 1 Month After Vaccination","description":"Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. CIs were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMCs were calculated using all participants with available data for the specified blood draw.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.18","spread":null},{"groupId":"OG001","value":"11.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.51","spread":null},{"groupId":"OG001","value":"41.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.31","spread":null},{"groupId":"OG001","value":"7.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.47","spread":null},{"groupId":"OG001","value":"22.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.76","spread":null},{"groupId":"OG001","value":"4.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.78","spread":null},{"groupId":"OG001","value":"11.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.89","spread":null},{"groupId":"OG001","value":"12.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.28","spread":null},{"groupId":"OG001","value":"19.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.28","spread":null},{"groupId":"OG001","value":"2.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.75","spread":null},{"groupId":"OG001","value":"15.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.16","spread":null},{"groupId":"OG001","value":"14.07","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.13","spread":null},{"groupId":"OG001","value":"8.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.62","spread":null},{"groupId":"OG001","value":"17.07","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Local Reactions Within 4 Days of Vaccination","description":"Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.0","spread":null},{"groupId":"OG001","value":"76.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","spread":null},{"groupId":"OG001","value":"52.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":null},{"groupId":"OG001","value":"21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"59.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":null},{"groupId":"OG001","value":"44.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Prespecified Systemic Reactions Within 4 Days of Vaccination","description":"Pre-specified systemic events (any fever 38 degrees Celsius \\[C\\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using a diary card. Participants may have been represented in more than 1 category.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null},{"groupId":"OG001","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"12.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Tenderness (Any)","Redness (Any)","Swelling (Any)","Redness (Moderate)","Swelling (Moderate)"]}}}